Canigen CPV2b
Canigen CPV2b is a vaccine comprised of live attenuated canine parvovirus 2b Strain CPV39 and is approved for use in puppies from the age of five weeks to induce protection against CPV serotypes 2b, 2a and 2.
The Center for Technology Licensing (CTL) is Cornell University's technology transfer office. We manage technology for Cornell's Ithaca campus, Weill Cornell Medicine, Cornell Tech, and Cornell AgriTech in Geneva.
Department: Baker Institute for Animal Health
Collie Eye Anomaly/Choroidal Hypoplasia (CEA) Test
The genetic test for CEA/CH provides a powerful management tool for the breeder. This genetic test can distinguish all three genetic states – normal, carrier and affected. With this information, the breeder can plan matings that avoid producing any affected dogs by always selecting one parent that is normal.
Congenital Stationary Night Blindness (CSNB) Test
The CSNB test is a DNA-based test that provides, for the first time, a method to unequivocally identify CSNB, in the Briard. This will control the gene frequency in the breed, so as to prevent producing puppies affected with the disease. The CSNB test enables 100% accurate identification of dogs who do not carry disease genes.
prcd-PRA Test
The prcd-PRA test is done on a small sample of blood from the dog. The test analyzes the specific DNA mutation causing the prcd-PRA. The test detects the mutant, abnormal gene copy and the normal gene copy. The result of the test is a genotype and allows separation of dogs into three groups: Normal/Clear (homozygous normal), Carrier (heterozygous), and Affected (homozygous mutant).
RD/OSD Test
The Inherited Retinal Dysplasia (RD)/OculoSkeletal Dysplasia (OSD) test is done on a small sample of blood obtained by a veterinarian or on a cheek swab. The test will identify dogs as being Normal, Carrier, or Affected with OSD. It is expected that many, but not all, carriers will show significant retinal dysplasia-retinal folding.